

## ASX ANNOUNCEMENT

21 February 2024

# Results of General Meeting and appointment of auditor



**Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company")** hereby provides the results of its General Meeting of shareholders held on 21 February 2024.

Information required to be disclosed by the Company in accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act is following.

The Company confirms that BDO Audit (WA) Pty Ltd ("**BDO**") has been appointed as auditor of LGP following approval by shareholders at the General Meeting today.

**ENDS**

**BY ORDER OF THE COMPANY SECRETARY**



**Alistair Warren**  
Company Secretary

Resolution	For	Against	Abstain	Chairman's discretion
1	Withdrawn	Withdrawn	Withdrawn	Withdrawn
2	77,015,073 99.09%	154,071 0.20%	827,885 -	544,373 0.71%

Resolution	Type	Voting method	Result	For	Against	Abstain
1 – Approval of capital reduction and in-specie distribution of shares	Ordinary	Withdrawn	Withdrawn	Withdrawn	Withdrawn	Withdrawn
2 – Approval of change of auditor	Ordinary	Poll	Carried	79,247,896 99.81%	154,071 0.19%	827,885 -



For further information please contact:

**Alistair Warren**  
**Company Secretary**  
Little Green Pharma  
E: [a.warren@lgp.global](mailto:a.warren@lgp.global)  
T: +61 8 6280 0050

**Paul Long**  
**Chief Executive Officer**  
Little Green Pharma  
E: [p.long@lgp.global](mailto:p.long@lgp.global)  
T: +61 8 6280 0050

## About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, with its Danish facility being one of the largest GMP medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor GMP production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: [www.littlegreenpharma.com](http://www.littlegreenpharma.com)

## Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: [www.computershare.com.au/easyupdate/lgp](http://www.computershare.com.au/easyupdate/lgp)